Retrophin appoints John Orwin to the Board of Directors

– USA, CA – Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company’s Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc., a biopharmaceutical company focused on developing treatments for patients with conditions that are often overlooked and undertreated.

“John’s operational and commercial expertise strengthens our Board and will be invaluable to Retrophin as we advance our late-stage pipeline towards commercialization while maximizing the potential of our approved therapies,” said Stephen Aselage, chief executive officer of Retrophin. “We are very pleased John is joining us at this exciting time and look forward to his leadership.”

Mr. Orwin is a biopharmaceutical industry veteran with more than 25 years of experience. He has served as chief executive officer of Relypsa since 2013. Previously, Mr. Orwin was chief executive officer and a director of Affymax. Before joining Affymax, Mr. Orwin held leadership positions in marketing, sales, and operations at Genentech, Johnson and Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough. Mr. Orwin currently serves as a director of Seattle Genetics and Array BioPharma. Mr. Orwin earned a bachelor’s degree from Rutgers University and master’s degree in business administration from New York University.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage candidates targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products, Thiola, Cholbam, and Chenodal.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>